Nevertheless, Dexa attenuated BV6-stimulated non-canonical NF-κB activation in ALL cell lines, which is consistent with other reports showing that glucocorticoids such as Dexa can block NF-κB [29–31]. Here, NFKB1 is linked to acute lymphoblastic leukemia.